Project description:Profiling of miRNA expression in mouse SHAM kidneys 9–12 weeks old male C57BL/6 mice were purchased from Charles River. Mice underwent anesthesia by intraperitoneal injection of pentobarbital (50 mg/kg body weight) and were subjected to Unilateral Ureteral Obstruction (UUO). After standard laparotomy, the left proximal ureter was exposed and ligated with 4-0 silk at two points. The sham operation consisted of a similar identification of the left ureter without ligation. Treated (S numbers) and non-treated (C numbers) mice miRNA expressions were then compared.
Project description:RNA-sequencing of mouse left kidneys for which the left ureter was obstructed (UUO) or not obstructed (sham) animals, isolated 7 days after the surgery in normal mice and mice in which the Kdm6a gene was deleted from tubule epithelial cells
Project description:The goal of this project is to obtain the expression pattern of miRNAs in wild type kidneys at various ages during development. The data is obtained from mouse kidneys of ages P0, P7, P14, P21 and P35. The analysis compares the expression levels of miRNAs between the age groups.
Project description:The microRNAs (miRNAs) that can influence diabetic kidney disease (DKD) have not been fully characterized. The aim of this study was to identify the miRNAs that affect DKD and could be used as specific biomarkers or therapeutic agents. First, kidneys from two DKD mouse models were screened for differences in miRNA expression from control mice. We found that miRNA-125b-5p and miRNA-181-5p were specifically differentially expressed in the kidneys of DKD mice. Next, we administered miRNA-181b-5p-mimic to DKD mice, which reduced the albuminuria and abnormal mesangial expansion. Pathway analysis revealed that overexpression of miRNA-181-5p significantly altered the expression of 51 genes in the kidneys of DKD mice. Furthermore, the serum level of miRNA-125b-5p was significantly higher and that of miRNA-181-5p was lower in patients with DKD than in patients with other kidney diseases. These results suggest that miRNA-125b-5p and miRNA-181b-5p may represent novel diagnostic biomarkers and that miRNA-181b-5p may represent a therapeutic target for DKD.